IMRX (Immuneering) 3-Year Share Buyback Ratio : -5.70% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immuneering 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Immuneering's current 3-Year Share Buyback Ratio was -5.70%.

The historical rank and industry rank for Immuneering's 3-Year Share Buyback Ratio or its related term are showing as below:

IMRX' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -7 Med: -5.7 Max: -3.4
Current: -5.7

During the past 6 years, Immuneering's highest 3-Year Share Buyback Ratio was -3.40%. The lowest was -7.00%. And the median was -5.70%.

IMRX's 3-Year Share Buyback Ratio is ranked better than
62.95% of 1263 companies
in the Biotechnology industry
Industry Median: -9.8 vs IMRX: -5.70

Competitive Comparison of Immuneering's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Immuneering's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuneering's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuneering's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Immuneering's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Immuneering 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Immuneering (NAS:IMRX) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Immuneering 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Immuneering's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuneering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuneering Corp (NAS:IMRX) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Second Floor, Cambridge, MA, USA, 02142

Website

https://www.immuneering.com

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Harold Eugene Brakewood	officer: Chief Business Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Mallory Morales	officer: Vice President, Finance	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Peter Feinberg	director	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Leah R Neufeld	officer: Chief People Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Brett Matthew Hall	officer: Chief Scientific Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Benjamin J. Zeskind	director, 10 percent owner, officer: President and CEO	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Ann E Berman	director	255 STATE STREET, BOSTON MA 02109
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Michael Bookman	officer: General Counsel and Secretary	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Biren Amin	officer: CFO, Treasurer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Scott Barrett	officer: Chief Medical Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142